Literature DB >> 32556897

Duration of opioid use and association with socioeconomic status, daily dose and formulation: a two-decade population study in Queensland, Australia.

Adeleke D Adewumi1,2,3, Joemer C Maravilla4, Rosa Alati5, Samantha A Hollingworth6, Xuelei Hu7, Bill Loveday8, Jason P Connor9,10.   

Abstract

Background There is an association between the duration of prescription opioids use and an increased risk of serious harm, often unintentional. Objective (1) Describe the trends in duration of prescription opioids dispensing and, (2) determine the risk of long-term use (≥4 months) based on patients' socioeconomic status, daily dose in oral daily morphine milligram equivalent, and opioid formulation. Setting Residents of Queensland (2,827,727), Australia from the age 18 years and who were dispensed pharmaceutical opioids from 1 January 1997 to 31 December 2018. Method Retrospective, longitudinal population-based analysis using data obtained from the Monitoring of Drugs of Dependence system of the Monitored Medicines Unit of Queensland Health. Main outcome measure Contribution of socioeconomic status, and daily dose and opioid formulation (modified-release or immediate-release) to the risk of long-term opioid use. Results There was little difference between the number of patients dispensed opioids for ≥4 months and ≤3 months between 1997 and 2011. Thereafter, the number for those using opioids long-term increased. The highest risk of having opioids dispensed for ≥4 months were for patients in the lowest level of socioeconomic status (adjusted odds ratio 1.36; 95% CI, 1.34, 1.38), compared to people in the highest socioeconomic status areas, followed by the low-socioeconomic status areas, mid-socioeconomic status areas, and high-socioeconomic status areas respectively. The risk of being dispensed prescription opioids for ≥4 months significantly increased as the dose increased: adjusted odds ratio 1.73; 95% CI, 1.71, 1.75, adjusted odds ratio 1.89; 95% CI, 1.87, 1.92, and adjusted odds ratio 3.63; 95% CI, 3.58, 3.69 for the ≥20 to <50 oral daily morphine milligram equivalent, ≥50 to <100 oral daily morphine milligram equivalent and ≥100 oral daily morphine milligram equivalent dose categories, respectively. Conclusion Higher doses and living in a low socioeconomic status areas were associated with increased risk of long-term dispensing of opioid prescriptions.

Entities:  

Keywords:  Australia; Duration of use; Opioids; Queensland; Socioeconomic status

Year:  2020        PMID: 32556897     DOI: 10.1007/s11096-020-01079-0

Source DB:  PubMed          Journal:  Int J Clin Pharm


  37 in total

Review 1.  Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction.

Authors:  Bridget A Martell; Patrick G O'Connor; Robert D Kerns; William C Becker; Knashawn H Morales; Thomas R Kosten; David A Fiellin
Journal:  Ann Intern Med       Date:  2007-01-16       Impact factor: 25.391

Review 2.  The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop.

Authors:  Roger Chou; Judith A Turner; Emily B Devine; Ryan N Hansen; Sean D Sullivan; Ian Blazina; Tracy Dana; Christina Bougatsos; Richard A Deyo
Journal:  Ann Intern Med       Date:  2015-02-17       Impact factor: 25.391

3.  Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy.

Authors:  Matthew Miller; Catherine W Barber; Sarah Leatherman; Jennifer Fonda; John A Hermos; Kelly Cho; David R Gagnon
Journal:  JAMA Intern Med       Date:  2015-04       Impact factor: 21.873

4.  Prescribed Dose of Opioids and Overdose: A Systematic Review and Meta-Analysis of Unintentional Prescription Opioid Overdose.

Authors:  Adeleke D Adewumi; Samantha A Hollingworth; Joemer C Maravilla; Jason P Connor; Rosa Alati
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

Review 5.  Opioids in chronic non-cancer pain: systematic review of efficacy and safety.

Authors:  Eija Kalso; Jayne E Edwards; Andrew R Moore; Henry J McQuay
Journal:  Pain       Date:  2004-12       Impact factor: 6.961

Review 6.  The prevalence of chronic pain with an analysis of countries with a Human Development Index less than 0.9: a systematic review without meta-analysis.

Authors:  Raga A Elzahaf; Osama A Tashani; Biddy A Unsworth; Mark I Johnson
Journal:  Curr Med Res Opin       Date:  2012-07-02       Impact factor: 2.580

7.  Risk of adverse health outcomes with increasing duration and regularity of opioid therapy.

Authors:  Leonard J Paulozzi; Kun Zhang; Christopher M Jones; Karin A Mack
Journal:  J Am Board Fam Med       Date:  2014 May-Jun       Impact factor: 2.657

8.  Trends in long-term opioid therapy for chronic non-cancer pain.

Authors:  Denise Boudreau; Michael Von Korff; Carolyn M Rutter; Kathleen Saunders; G Thomas Ray; Mark D Sullivan; Cynthia I Campbell; Joseph O Merrill; Michael J Silverberg; Caleb Banta-Green; Constance Weisner
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-12       Impact factor: 2.890

9.  Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study.

Authors:  Mark D Sullivan; Mark J Edlund; Ming-Yu Fan; Andrea DeVries; Jennifer Brennan Braden; Bradley C Martin
Journal:  Pain       Date:  2008-06-10       Impact factor: 6.961

10.  Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study.

Authors:  Gabriel A Brat; Denis Agniel; Andrew Beam; Brian Yorkgitis; Mark Bicket; Mark Homer; Kathe P Fox; Daniel B Knecht; Cheryl N McMahill-Walraven; Nathan Palmer; Isaac Kohane
Journal:  BMJ       Date:  2018-01-17
View more
  1 in total

1.  Association of sociodemographic factors with the prescription pattern of opioids for dental patients: A systematic review protocol.

Authors:  Alex Junio Silva Cruz; Lucas Guimarães Abreu; Suellen da Rocha Mendes; Lia Silva de Castilho; Mauro Henrique Nogueira Guimarães de Abreu
Journal:  PLoS One       Date:  2021-08-05       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.